

JC10 Rec'd PCT/PTO 23 MAY 2005  
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Jacques SCHRENZEL et al. : **Mail Stop: PCT**  
Serial No. 10/530,910 : Attorney Docket No. 2005\_0613A  
Filed April 8, 2005 :

ANALYTICAL CHIP WITH AN ARRAY OF IMMOBILIZED  
SPECIFIC RECOGNITION ELEMENTS FOR THE  
DETERMINATION OF CLINICALLY RELEVANT BACTERIA  
AND ANALYTICAL METHOD BASED THEREON

[Corresponding to PCT/EP2003/010626  
Filed September 24, 2003]

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application  
PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No.  
\_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the  
above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Jacques SCHRENZEL et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
May 23, 2005

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: May 23, 2005

ATTY DOCKET NO.  
2005\_0613ASERIAL NO.  
10/530,910APPLICANT  
Jacques SCHRENZEL et al.FILING DATE  
April 8, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,478,755	12/1995	Attridge et al.			
	AB	5,841,143	11/1998	Tuma et al.			
	AC	5,006,716	4/1991	Hall			
	AD	4,649,280	3/1987	Holland et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE	02/059348	8/2002	WO			
	AF	97/29212	8/1997	WO			
	AG	95/33197	12/1995	WO			
	AH	95/33198	12/1995	WO			
	AI	96/35940	11/1996	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	B. P. Nelson et al., "Label-Free Detection of 16S Ribosomal RNA Hybridization on Reusable DNA Arrays using Surface Plasmon Resonance Imaging", Environmental Microbiology, Vol. 4, No. 11, pp. 735-743, 2002.
	AK	B. P. Nelson et al., "Surface Plasmon Resonance Imaging Measurements of DNA and RNA Hybridization Adsorption onto DNA Microarrays", Analytical Chemistry, Vol. 73, No. 1, pp. 1-7, January 1, 2001.
	AL	J. Small et al., "Direct Detection of 16S rRNA in Soil Extracts by Using Oligonucleotide Microarrays", Applied and Environmental Microbiology, Vol. 67, No. 10, pp. 4708-4716, October 2001.
	AM	B. Hirschel et al., "Fatal Infection with a Novel Unidentified Mycobacterium in a Man with the Acquired Immunodeficiency Syndrome", New England Journal of Medicine, Vol. 323, No. 2, pp. 109-112, July 12, 1990.
	AN	E. C. Bottger et al., "Disseminated <i>Mycobacterium genavense</i> Infection in Patients with AIDS", The Lancet, Vol. 340, pp. 76-80, July 11, 1992.
	AO	D. J. Marshall et al., "Determination of Hepatitis C Virus Genotypes in the United States by Cleavase Fragment Length Polymorphism Analysis", Journal of Clinical Microbiology, Vol. 35, No. 12, pp. 3156-3162, December 1997.

EXAMINER

DATE CONSIDERED

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: May 23, 2005

ATTY DOCKET NO.  
2005\_0613AAL NO.  
10/530,910APPLICANT  
Jacques SCHRENZEL et al.FILING DATE  
April 8, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	6,136,541	10/2000	Gulati			
	BB	6,142,681	11/2000	Gulati			
	BC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BD	00/75644	12/2000	WO			
	BE	01/43875	6/2001	WO			
	BF	01/79821	10/2001	WO			
	BG	01/88511	11/2001	WO			
	BH	01/13096	2/2001	WO			
	BI	01/55691	8/2001	WO			
	BJ	01/55760	8/2001	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BK	S. Sreevatsan et al., "Comparative Evaluation of Cleavase Fragment Length Polymorphism with PCR-SSCP and PCT-RFLP to Detect Antimicrobial Agent Resistance in <i>Mycobacterium tuberculosis</i> ", Molecular Diagnosis, Vol. 3, No. 2, pp. 81-91, June 1998.
	BL	S. Rossetti et al., "Detection of Mutations in Human Genes by a New Rapid Method: Cleavage Fragment Length Polymorphism Analysis (CFLPA)", Molecular and Cellular Probes, Vol. 11, pp. 155-160, 1997.
	BM	S. X. Wang et al., "Evaluation of Three Nucleic Acid Amplification Methods for Direct Detection of <i>Mycobacterium tuberculosis</i> Complex in Respiratory Specimens", Journal of Clinical Microbiology, Vol. 37, No. 6, pp. 1932-1934, June 1999.
	BN	R. Pasternack et al., "Comparison of a Transcription-Mediated Amplification Assay and Polymerase Chain Reaction for Detection of <i>Chlamydia trachomatis</i> in First-Void Urine", Eur. J. Clin. Microbiol. Infect. Dis., Vol. 18, pp. 142-144, 1999.
	BO	J. Groen et al., "Evaluation of a Fully Automated Glycoprotein G-2 based Assay for the Detection of HSV-2 Specific IgG Antibodies in Serum and Plasma", Journal of Clinical Virology, Vol. 12, pp. 193-200, 1999.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: May 23, 2005

ATTY DOCKET NO.  
2005\_0613AAL NO.  
10/530,910APPLICANT  
Jacques SCHRENZEL et al.FILING DATE  
April 8, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
	CL						
	CM						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	CN	W. K. Roth et al., "Feasibility and Efficacy of Routine PCR Screening of Blood Donations for Hepatitis C Virus, Hepatitis B Virus, and HIV-1 in a Blood-Bank Setting", The Lancet, Vol. 353, pp. 359-363, January 30, 1999.
	CO	A. Doglio et al., "Second Generation of the Automated Cobas Amplicor HCV Assay Improves Sensitivity of Hepatitis C Virus RNA Detection and Yields that are more Clinically Relevant", Journal of Clinical Microbiology, Vol. 37, No. 5, pp. 1567-1569, May 1999.
	CP	S. Tyagi et al., "Molecular Beacons: Probes that Fluoresce upon Hybridization", Nature Biotechnology, Vol. 14, pp. 303-308, March 1996.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: May 23, 2005

ATTY DOCKET NO.  
2005\_0613ASERIAL NO.  
10/530,910APPLICANT  
Jacques SCHRENZEL et al.FILING DATE  
April 8, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	DB						
	DC						
	DD						
	DE						
	DF						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	DG	C. A. Gelfand et al., "A Quantitative Method for Evaluating the Stabilities of Nucleic Acids", Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 6113-6118, May 1999.
	DH	C. A. Heid et al., "Real Time Quantitative PCR", Genome Research, Vol. 6, pp. 986-994, 1996.
	DI	P. Belgrader et al., "PCR Detection of Bacteria in Seven Minutes", Science, Vol. 284, pp. 449-450, April 16, 1999.
	DJ	M. C. Enright et al., "Phylogenetic Relationships between some Member of the Genera <i>Neisseria</i> , <i>Acinetobacter</i> , <i>Moraxella</i> , and <i>Kingella</i> based on Partial 16S Ribosomal DNA Sequence Analysis", International Journal of Systematic Bacteriology, Vol. 44, No. 3, pp. 387-391, July 1994.
	DK	D. A. Relman et al., "Identification of the Uncultured Bacillus of Whipple's Disease", New England Journal of Medicine, Vol. 327, No. 5, pp. 293-301, July 30, 1992.
	DL	R. A. Zimmermann et al., "The Ribosomal Proteins and rRNA Recognize one Another", The Ribosome: Structure, Function, Antibiotics, and Cellular Interactions", pp. 93-104,
	DM	D. J. Ecker et al., "RNA as A Small-Molecule Drug Target: Doubling the Value of Genomics", DDT, Vol. 4, No. 9, pp. 420-429, September 9, 1999.
	DN	W. C. W. Chan et al., "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection", Science, Vol. 281, pp. 2016-2018, September 25, 1998.

EXAMINER

DATE CONSIDERED